Haemonetics Corporation, a healthcare company, provides medical products and solutions.
$122.94+0.19%
报价 2026-11-13
市值
$5.6B
EV
$6.47B
PE (TTM)
58.9x
预期 PE (FY2027)
23.1x
52 周区间距高点 -3.5%
$52.24$127.42
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-03 | 1.1x | 5.09 → 6.19（1.2x） | 19.9 |
| FY+32029-03 | 1.2x | 5.09 → 7.18（1.4x） | 17.1 |
毛利率 57% · TTM 收入 $1382M · 基数 EPS 5.09（调整后）
电话会信号
辅助标签Q2 20272026-11-05
扩产上调指引供不应求
指引 上调
信心 4
分析师 4
“We expect stronger operating leverage as volumes scale and transitory costs diminish, setting up FY2028 and beyond.”
原文引用（3）
- 扩产：we are going to have to expand manufacturing capacity
- 上调指引：We now expect organic growth of 6%-9%, up from 4%-7%
- 供不应求：We are scaling capacity to supply CSL while supporting continued strong demand across our customer base.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| HAEHaemonetics Corporation | $5.6B | +0.2% | +8.6% | 59.8% | 58.9x | 24.8x | 18.9x | |
| CONConcentra Group Holdings Parent, Inc. | $5.38B | -1.0% | +9.6% | 31.7% | 22.9x | 14.2x | 13.0x | |
| ITGRInteger Holdings Corporation | $4.31B | +0.2% | -1.7% | 24.3% | 34.2x | 18.0x | 38.2x | |
| BHCBausch Health Companies Inc. | $3.13B | +1.2% | +6.8% | 75% | – | 8.9x | 1.7x | |
| WRBYWarby Parker Inc. | $2.99B | +2.7% | +11.2% | 54.4% | 502.5x | 49.6x | 154.1x | GARP |
| BEAMBeam Therapeutics Inc. | $2.36B | -5.0% | +6.9% | 100% | – | – | – | |
| XRAYDENTSPLY SIRONA Inc. | $1.83B | -0.9% | -3.5% | 53% | – | 11.8x | 18.9x | |
| LMATLeMaitre Vascular, Inc. | $1.79B | +0.8% | +11.3% | 71.7% | 42.4x | 28.8x | 26.7x | |
| QDELQuidelOrtho Corporation | $736.9M | +1.1% | -6.9% | 42.6% | – | 11.5x | – | |
| 同行中位数 | – | – | +6.9% | 53.7% | 38.3x | 14.2x | 22.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-27 Q1 2027 | 2026-03-28 Q4 2026 | 2025-12-27 Q3 2026 | 2025-09-27 Q2 2026 | 2025-06-28 Q1 2026 | 2025-03-31 Q4 2025 | 2024-12-28 Q3 2025 | 2024-09-28 Q2 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $339.4M | $346.4M | $339M | $327.3M | $321.4M | $330.6M | $348.5M | $345.5M |
| Gross Margin | 59.8% | 57.2% | 56.5% | 56% | 59.7% | 55% | 57.4% | 55.3% |
| Operating Margin | 16.9% | 14.9% | 20.5% | 20.6% | 16.8% | 15.6% | 16.9% | 15% |
| Net Income | $33M | $-20.1M | $44.7M | $38.7M | $34M | $58M | $37.5M | $33.8M |
| Diluted EPS | 0.72 | -0.44 | 0.95 | 0.81 | 0.7 | 1.17 | 0.74 | 0.66 |
| Operating Cash Flow | $52.3M | $70.9M | $93.6M | $111.3M | $17.4M | $116.6M | $43.8M | $48.8M |